Flavonoid‐rich fraction of Bauhinia forficata Link leaves prevents the intestinal toxic effects of irinotecan chemotherapy in IEC‐6 cells and in mice. (3rd October 2018)

• Record Type: Journal Article
• Authors: Cechinel‐Zanchett, Camile Cecconi; Boeing, Thaise; Somensi, Lincon Bordignon; Steimbach, Viviane Miranda Bispo; Campos, Adriana; Krueger, Clarissa de Medeiros Amorm; Schultz, Cristiany; Sant'ana, Débora de Mello Gonçales; Cechinel‐Filho, Valdir; Mota da Silva, Luísa; Faloni de Andrade, Sérgio
• Is Part Of: Phytotherapy research. Volume 33:Number 1(2019)
• Page Start: 90
• Page End: 106
• Publication Date: 2018-10-03
• Subjects: duodenum -- intestinal mucositis -- kaempferitrin -- melanoma; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.6202
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract : This study evaluated the effects of flavonoid‐rich fraction from Bauhinia forficata leaves (FRF‐BF), against intestinal toxicity induced by irinotecan. The leaves of this plant are used like tea in Brazilian folk medicine, and it is rich in flavonoids, mainly kaempferitrin. First, the chemopreventive effects of FRF‐BF and kaempferitrin were evaluated in intestinal cells (IEC‐6 cells) exposed to irinotecan. Next, the effects were evaluated against irinotecan‐induced mucositis in mice. Lastly, melanoma was induced in C57BL/6 mice to evaluate FRF‐BF interference on irinotecan antitumor activity. The results showed that FRF‐BF and kaempferitrin exert no cytotoxic effects in IEC‐6 cells and confirmed that pretreatment with FRF‐BF and kaempferitrin displays chemoprotective effects against cytotoxicity induced by irinotecan. Interestingly, the FRF‐BF (100 mg/kg, p.o) reduced the intestinal motility in mice and attenuated parameters linked to irinotecan‐induced intestinal mucositis, including diarrhea, histological damage, depletion of duodenal GSH, amount of TNF‐α, and MPO activity in the small intestine. Also, FRF‐BF does not interfere in the antitumor activity of irinotecan and exerted antitumoral activity in murine melanoma. In conclusion, FRF‐BF (100 mg/kg, p.o) presents promising pharmacological potential to prevent and attenuate the severity of intestinal mucositis during chemotherapy treatment, related to the presence of kaempferitrin.